Drägerwerk stock: Analysts raise targets after 2030 plan
Published on 11/19/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalysts Reprice Long-Term Potential
- Two analyst houses raised their Drägerwerk price targets after the Ambition 2030 presentation.
- The recommendations remain divided between Buy and Hold.
- Execution in medical and safety technology will determine whether the long-term plan supports higher profitability.
Drägerwerk stock: analysts raise targets after Ambition 2030 plan
Two analyst houses raised their price targets for Drägerwerk's preferred shares on Thursday, November 19, according to Goldesel. One house lifted its target from 135 euros to 176 euros and reaffirmed a Buy rating. Another raised its target from 105 euros to 125 euros while keeping a Hold recommendation.
Targets diverge despite new ambition
The revisions followed Drägerwerk's Capital Markets Day in Lübeck on November 18. The medical and safety technology group presented an Ambition 2030 plan that targets higher revenue and profitability through growth in both divisions, pricing measures and productivity improvements.
The different recommendations point to a divided assessment of how quickly the strategy can translate into recurring revenue and stronger margins. For investors, the key issue is execution: the plan requires progress in medical technology as well as continued expansion in selected safety technology markets.
Execution becomes the next test
Drägerwerk's current 2026 outlook remains the near-term reference for assessing delivery against the longer-term plan. The next quarters should show whether sales growth, cost control and operating leverage develop together.
German equities are covered in the current market reports.
More news and analyses on Drägerwerk stock.
Drägerwerk AG & Co. KGaA
- ISIN: DE0005550636
- Ticker: DRW3
- Business: Medical and safety technology
- Analyst targets: 176 euros and 125 euros
